These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 28628405)

  • 1. Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan.
    Mugikura S; Fujimura M; Takahashi S; Takase K
    Radiology; 2017 Jul; 284(1):301-303. PubMed ID: 28628405
    [No Abstract]   [Full Text] [Related]  

  • 2. Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan.
    Mugikura S; Fujimura M; Takahashi S
    Radiology; 2016 May; 279(2):652-3. PubMed ID: 27089195
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemodynamic stress distribution reflects ischemic clinical symptoms of patients with moyamoya disease.
    Takahashi S; Tanizaki Y; Kimura H; Akaji K; Nakazawa M; Yoshida K; Mihara B
    Clin Neurol Neurosurg; 2015 Nov; 138():104-10. PubMed ID: 26318361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substraction acetazolamide SPECT co-registered to MRI in moyamoya disease: quantitative cerebrovascular reserve map.
    Cortés J; Arias-Rivas S; Rodriguez-Yañez M; Blanco M; Aguiar P
    Clin Nucl Med; 2014 Apr; 39(4):399-401. PubMed ID: 23510893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebral vasodilatory capacity mapping using technetium-99m-DTPA-HSA SPECT and acetazolamide in moyamoya disease.
    Inoue Y; Momose T; Machida K; Honda N; Tsutsumi K
    J Nucl Med; 1993 Nov; 34(11):1984-6. PubMed ID: 8229245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain Perfusion Before and After Surgical Treatment of Moyamoya Disease.
    Drouet C; Morel O; Thines L; Porot C; Boulahdour H
    Clin Nucl Med; 2017 May; 42(5):e269-e272. PubMed ID: 28221195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan: Response.
    Haller S; Barkhof F; Thomas D; Lovblad KO; Golay X; Zaharchuk G
    Radiology; 2017 Jul; 284(1):301-303. PubMed ID: 28896007
    [No Abstract]   [Full Text] [Related]  

  • 8. Cerebral blood flow study in patients with moyamoya disease evaluated by IMP SPECT.
    Hoshi H; Ohnishi T; Jinnouchi S; Futami S; Nagamachi S; Kodama T; Watanabe K; Ueda T; Wakisaka S
    J Nucl Med; 1994 Jan; 35(1):44-50. PubMed ID: 8271059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preoperative and postoperative cerebral blood flow and vasoreactivity in childhood moyamoya disease.
    Liu HM; Peng SS; Li YW
    Keio J Med; 2000 Feb; 49 Suppl 1():A86-9. PubMed ID: 10750348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usefulness of 123I-amphetamine SPECT in evaluation of cerebral circulation by the acetazolamide test in patients with moyamoya disease].
    Fuse T; Takagi T
    No To Hattatsu; 1993 Mar; 25(2):183-5. PubMed ID: 8461169
    [No Abstract]   [Full Text] [Related]  

  • 11. Cerebral versus myocardial stress perfusion imaging: role of pharmacological intervention in the diagnostic assessment of flow reserve.
    Machac J; Vallabhajosula S
    J Nucl Med; 1994 Jan; 35(1):41-3. PubMed ID: 8271058
    [No Abstract]   [Full Text] [Related]  

  • 12. Prediction of the clinical outcome of pediatric moyamoya disease with postoperative basal/acetazolamide stress brain perfusion SPECT after revascularization surgery.
    So Y; Lee HY; Kim SK; Lee JS; Wang KC; Cho BK; Kang E; Lee DS
    Stroke; 2005 Jul; 36(7):1485-9. PubMed ID: 15947261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constant-infusion H(2)15O PET and acetazolamide challenge in the assessment of cerebral perfusion status.
    Weber B; Westera G; Treyer V; Burger C; Khan N; Buck A
    J Nucl Med; 2004 Aug; 45(8):1344-50. PubMed ID: 15299060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPECT measurements of cerebral blood volume before and after acetazolamide in occlusive cerebrovascular diseases.
    Inoue Y; Momose T; Machida K; Honda N; Nishikawa J; Sasaki Y
    Radiat Med; 1994; 12(5):225-9. PubMed ID: 7863027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive brain infarction involving deep structures during an acetazolamide-challenged single-photon emission computed tomography scan in a patient with moyamoya disease.
    Chong S; Park JD; Chae JH; Cheon JE; Kim SK; Phi JH; Lee JY; Paeng JC; Wang KC
    Childs Nerv Syst; 2017 Nov; 33(11):2029-2033. PubMed ID: 28689345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moyamoya disease.
    Yonekawa Y; Kahn N
    Adv Neurol; 2003; 92():113-8. PubMed ID: 12760172
    [No Abstract]   [Full Text] [Related]  

  • 17. Imaging of cerebrovascular reserve and oxygenation in Moyamoya disease.
    Ni WW; Christen T; Rosenberg J; Zun Z; Moseley ME; Zaharchuk G
    J Cereb Blood Flow Metab; 2017 Apr; 37(4):1213-1222. PubMed ID: 27207169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical Critical Hyperkalemia After Acetazolamide for Cerebrovascular Reactivity Study: A Case Report.
    Burbridge MA; Jaffe RA
    A A Pract; 2020 Feb; 14(3):69-71. PubMed ID: 31770135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cerebral blood flow reactivity to hyperventilation in children with spontaneous occlusion of the circle of willis (moyamoya disease)].
    Isobe M; Kuroda S; Kamiyama H; Abe H; Mitumori K
    No Shinkei Geka; 1992 Apr; 20(4):399-407. PubMed ID: 1570062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cerebral hemodynamics in adult ischemic-type patients with moyamoya disease compared with those of atherothrombotic middle cerebral artery occlusion].
    Idei M; Yamane K; Nishida M; Manabe K; Yokota A
    No To Shinkei; 2005 Feb; 57(2):131-5. PubMed ID: 15856759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.